CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 111 filers reported holding CLOVIS ONCOLOGY INC in Q4 2013. The put-call ratio across all filers is 0.91 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $13,132,000 | -44.0% | 193,117 | -32.1% | 0.04% | -45.6% |
Q3 2017 | $23,448,000 | -56.8% | 284,565 | -50.9% | 0.07% | -57.8% |
Q2 2017 | $54,249,000 | +41.0% | 579,397 | -4.1% | 0.16% | +40.0% |
Q1 2017 | $38,466,000 | +334.3% | 604,157 | +203.0% | 0.12% | +325.9% |
Q4 2016 | $8,856,000 | +89.2% | 199,373 | +53.5% | 0.03% | +92.9% |
Q3 2016 | $4,681,000 | -78.2% | 129,854 | -44.4% | 0.01% | -78.5% |
Q3 2015 | $21,470,000 | -70.0% | 233,469 | -71.3% | 0.06% | -65.6% |
Q2 2015 | $71,546,000 | +68.8% | 814,128 | +42.6% | 0.19% | +76.6% |
Q1 2015 | $42,391,000 | +36.5% | 571,080 | +3.0% | 0.11% | +35.4% |
Q4 2014 | $31,046,000 | +204.4% | 554,395 | +125.1% | 0.08% | +558.3% |
Q2 2014 | $10,200,000 | +0.2% | 246,306 | +67.7% | 0.01% | -47.8% |
Q1 2014 | $10,175,000 | -57.1% | 146,890 | -62.7% | 0.02% | -56.6% |
Q4 2013 | $23,726,000 | +30.2% | 393,659 | +31.3% | 0.05% | +26.2% |
Q3 2013 | $18,221,000 | -17.4% | 299,794 | -9.0% | 0.04% | -17.6% |
Q2 2013 | $22,066,000 | – | 329,441 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 407,416 | $14,259,560,000 | 8.34% |
Palo Alto Investors LP | 3,547,719 | $124,170,000 | 6.91% |
Antipodean Advisors LLC | 1,268,658 | $44,403,000 | 6.48% |
Redmile Group, LLC | 1,795,936 | $62,858,000 | 4.70% |
HealthCor Management, L.P. | 1,525,000 | $53,375,000 | 3.24% |
PointState Capital LP | 3,503,900 | $122,637,000 | 3.12% |
NEA Management Company, LLC | 1,139,890 | $39,896,000 | 2.54% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 612,500 | $21,438,000 | 2.44% |
PFM Health Sciences, LP | 2,078,440 | $72,745,000 | 2.21% |
Partner Investment Management, L.P. | 35,300 | $1,236,000 | 2.03% |